Valbenazine for Tardive Dyskinesia | FDA Approval The U.S. Food and Drug Administration today approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. Tardive dyskinesia is a serious side effect sometimes seen in patients who have been treated with antipsychotic medications, especially the older medications, for long periods to
Pimavanserin | First drug to treat hallucinations and delusions associated with Parkinson’s disease
Sorafenib A Tyrosine Kinase Inhibitor (TKI) for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma. FDA status: Approved Company: co-developed and co-marketed by Bayer and Onyx Pharmaceuticals.
Brivaracetam SV2A binding drug which exhibits it antiepileptic activity by blocking voltage sensitive neuronal Na channels (proposed mechanism). FDA status: Approved on February 2016 Company: UCB, Inc
Secukinumab A fully human anti-Interleukin 17-A monoclonal antibody for the treatment of moderate to severe plaque type Psoriasis. FDA status: Approved on January,2015 Company: Novartis
